Virginia Albiñana

663 total citations
30 papers, 471 citations indexed

About

Virginia Albiñana is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Cancer Research. According to data from OpenAlex, Virginia Albiñana has authored 30 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Genetics and 8 papers in Cancer Research. Recurrent topics in Virginia Albiñana's work include Vascular Anomalies and Treatments (17 papers), Tracheal and airway disorders (16 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Virginia Albiñana is often cited by papers focused on Vascular Anomalies and Treatments (17 papers), Tracheal and airway disorders (16 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Virginia Albiñana collaborates with scholars based in Spain, United States and Germany. Virginia Albiñana's co-authors include Luisa M. Botella, Carmelo Bernabéu, Lucía Recio-Poveda, Roberto Zarrabeitia, Ángel M. Cuesta, Eunate Gallardo‐Vara, Francisco Sanz‐Rodríguez, Luisa Ojeda‐Fernández, Ana Belén Perona Moratalla and José M. de Campos and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Virginia Albiñana

27 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Virginia Albiñana Spain 13 265 218 138 78 71 30 471
Lucía Recio-Poveda Spain 12 189 0.7× 150 0.7× 102 0.7× 43 0.6× 86 1.2× 24 388
H Plauchu France 11 307 1.2× 230 1.1× 151 1.1× 86 1.1× 107 1.5× 29 632
Sung Ok Park United States 5 169 0.6× 250 1.1× 94 0.7× 21 0.3× 280 3.9× 6 631
Kristine Jun United States 10 172 0.6× 83 0.4× 115 0.8× 11 0.1× 136 1.9× 14 593
Frederic A. M. Hennekam Netherlands 7 80 0.3× 91 0.4× 107 0.8× 14 0.2× 131 1.8× 11 390
Nicole Colwell United States 6 95 0.4× 39 0.2× 36 0.3× 2 0.0× 110 1.5× 9 319
Melanie Barz Germany 14 232 0.9× 79 0.4× 89 0.6× 70 1.0× 40 468
Nobuaki Funada Japan 7 290 1.1× 225 1.0× 92 0.7× 81 1.1× 16 488
Marta Padovan Italy 13 282 1.1× 79 0.4× 30 0.2× 91 1.3× 47 435
Erin Twohy United States 9 121 0.5× 138 0.6× 101 0.7× 75 1.1× 18 385

Countries citing papers authored by Virginia Albiñana

Since Specialization
Citations

This map shows the geographic impact of Virginia Albiñana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia Albiñana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia Albiñana more than expected).

Fields of papers citing papers by Virginia Albiñana

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia Albiñana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia Albiñana. The network helps show where Virginia Albiñana may publish in the future.

Co-authorship network of co-authors of Virginia Albiñana

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia Albiñana. A scholar is included among the top collaborators of Virginia Albiñana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia Albiñana. Virginia Albiñana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Botella, Luisa M., Marta Mascaraque, Virginia Albiñana, et al.. (2025). N-acetylcysteine and raloxifene boost photodynamic therapy against cutaneous squamous cell carcinoma by decreasing TGFβ1 secreted by cancer-associated fibroblasts. International Journal of Biological Sciences. 21(7). 3164–3182.
2.
López, Cristina M., Ángel M. Cuesta, Virginia Albiñana, et al.. (2024). Effect of 5β-dihydrotestosterone on vasodilator function and on cell proliferation. PLoS ONE. 19(10). e0312080–e0312080. 1 indexed citations
3.
Cuesta, Ángel M., et al.. (2024). Endothelial-to-Mesenchymal Transition in an Hereditary Hemorrhagic Telangiectasia-like Pediatric Case of Multiple Pulmonary Arteriovenous Malformations. International Journal of Molecular Sciences. 25(11). 6163–6163.
4.
Albiñana, Virginia, Lucía Recio-Poveda, Pilar González‐Peramato, et al.. (2022). Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences. 23(3). 1325–1325. 8 indexed citations
5.
Albiñana, Virginia, Lucía Recio-Poveda, Ángel M. Cuesta, et al.. (2021). The Endothelial Landscape and Its Role in Von Hippel–Lindau Disease. Cells. 10(9). 2313–2313. 6 indexed citations
6.
Albiñana, Virginia, Eunate Gallardo‐Vara, Lucía Recio-Poveda, et al.. (2020). Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease. Journal of Clinical Medicine. 9(9). 2740–2740. 10 indexed citations
7.
Albiñana, Virginia, Guillermo Giménez‐Gallego, Patricia Palacios, et al.. (2019). Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition). SHILAP Revista de lepidopterología. 3(3). e230–e243. 7 indexed citations
8.
Padial, Luis Rodrı́guez, et al.. (2019). Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial. BMJ Open Ophthalmology. 4(1). e000203–e000203. 13 indexed citations
9.
10.
Aguado, Tania, Rosario Granados, Susana Campuzano, et al.. (2019). 11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells. Scientific Reports. 9(1). 11916–11916. 3 indexed citations
11.
Albiñana, Virginia, Lucía Recio-Poveda, Roberto Zarrabeitia, & Luisa M. Botella. (2017). Current and emerging pharmacotherapies for hereditary hemorrhagic telangiectasia. Expert Opinion on Orphan Drugs. 5(8). 665–675. 2 indexed citations
12.
Albiñana, Virginia, et al.. (2017). Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet Journal of Rare Diseases. 12(1). 122–122. 23 indexed citations
13.
Albiñana, Virginia, Gemma Serrano‐Heras, Tomás Segura, et al.. (2015). Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet Journal of Rare Diseases. 10(1). 118–118. 37 indexed citations
14.
15.
Fontalba, Ana, José L. Fernández-Luna, Roberto Zarrabeitia, et al.. (2013). Copy number variations in endoglin locus: mapping of large deletions in Spanish families with hereditary hemorrhagic telangiectasia type 1. BMC Medical Genetics. 14(1). 121–121. 6 indexed citations
16.
Albiñana, Virginia, Lucía Recio-Poveda, Roberto Zarrabeitia, Carmelo Bernabéu, & Luisa M. Botella. (2012). Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thrombosis and Haemostasis. 108(7). 41–53. 45 indexed citations
17.
Albiñana, Virginia, Francisco Sanz‐Rodríguez, Lucía Recio-Poveda, Carmelo Bernabéu, & Luisa M. Botella. (2011). Immunosuppressor FK506 Increases Endoglin and Activin Receptor-Like Kinase 1 Expression and Modulates Transforming Growth Factor-β1 Signaling in Endothelial Cells. Molecular Pharmacology. 79(5). 833–843. 49 indexed citations
18.
Albiñana, Virginia, et al.. (2010). Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thrombosis and Haemostasis. 103(3). 441–451. 67 indexed citations
19.
Zarrabeitia, Roberto, et al.. (2010). A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT). Current Vascular Pharmacology. 8(4). 473–481. 31 indexed citations
20.
Fontalba, Ana, Africa Fernández-L, Virginia Albiñana, et al.. (2008). Mutation study of Spanish patients with Hereditary Hemorrhagic Telangiectasia. BMC Medical Genetics. 9(1). 75–75. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucía Recio-Poveda Breakdown of academic impact, for papers by H Plauchu Breakdown of academic impact, for papers by Sung Ok Park Breakdown of academic impact, for papers by Kristine Jun Breakdown of academic impact, for papers by Frederic A. M. Hennekam Breakdown of academic impact, for papers by Nicole Colwell Breakdown of academic impact, for papers by Melanie Barz Breakdown of academic impact, for papers by Nobuaki Funada Breakdown of academic impact, for papers by Marta Padovan Breakdown of academic impact, for papers by Erin Twohy
Rankless by CCL
2026